Navigation Links
Study Calls for Modification of CMS Conditions of Participation to Preserve Access to Life-Saving Liver Transplantations under Less than Optimal Conditions
Date:11/5/2011

SAN FRANCISCO, Nov. 4, 2011 /PRNewswire/ -- Adherence to strict outcome requirements imposed by the Centers for Medicare and Medicaid Services (CMS) has an adverse effect on liver transplantation centers performing life-saving liver transplantations under less than optimal conditions, according to researchers at Northwestern University. According to researcher Edward Wang, PhD, "While quality improvement initiatives aim to enhance post-transplant outcomes, the inadequately risk-adjusted criteria implemented by CMS might act as a disincentive to perform life-saving liver transplantation in high cardiovascular risk patients and limit the use of valuable donor organs of perceived lower quality."

That statement was made as part of a study that was presented on Sunday, November 6, 10:30 am, at the Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases. Researchers retrospectively examined the records of 65,601 adult recipients of deceased-donor liver transplantations performed between 1995 and 2010.

Examination of these records, which were part of the database of the Organ Procurement and Transplant Network (OPTN) of the United Network of Organ Sharing (UNOS), revealed that access to liver transplantation for high-risk patients suffers under the CMS Conditions of Participation (CoP). Specifically, researchers looked at trends in the Donor Risk Index and the recipient Cardiovascular Risk Index before and after implementation of the CoP. What they found was that 71 percent of transplant centers experienced a decline in either or both of the risk indices.

According to Dr. Wang, "Our findings suggest that regulatory oversight by the CMS on liver transplantation programs has led to the unintended consequence of risk-averse behavior by transplant centers. As a result, transplant centers under strict oversight might be reluctant to perform life-saving liver transplantation in high cardiovascular risk patients and/or to accept suboptimal donor organs.  Modification of risk adjustment, which is integral to performance measurement, is necessary to preserve access to liver transplantation among high risk recipients and sustain the optimal use of marginal donors."

The conclusion reached is that risk adjustment must be modified to preserve access to liver transplantation by high cardiovascular risk recipients and the use of marginal donor organs. "We believe that there is a need for mitigating factors that could justify inferior outcomes by transplant centers under specific circumstances. Failure to reach consensus on such a mechanism would result in continued risk-averse behavior by transplant centers undermining innovation and hampering advancement of the field of transplantation and ultimately compromising patient care," said Dr. Wang.

Abstract title:

Donor and Recipient Risk Aversion in Liver Transplantation

AASLD is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent and cure liver diseases. This year's Liver Meeting®, held in San Francisco, California, November 4 – 8, will bring together more than 8,000 researchers from 55 countries.

A press room will be available from November 5 at the annual meeting. For copies of abstracts and press releases, or to arrange researcher interviews, contact Gregory Bologna at 703-299-9766.

Press releases and all abstracts are available online at www.aasld.org.

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com.


'/>"/>
SOURCE American Association for the Study of Liver Diseases (AASLD)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tibotec to Present Final Safety and Efficacy Results From Phase 2b PILLAR Study of Once-Daily TMC435 in Late-Breaker at AASLD
2. Study Shows Efficacy of C1-Esterase Inhibitor Concentrate in Treating Acute Attacks of Hereditary Angioedema in Children and Adolescents
3. New 12 Week, Interferon-Free Treatment Arms Added to All-Oral Combination Study of PSI-7977 and Daclatasvir (BMS-790052) for HCV Genotype 1
4. Study Shows New Medication Effectively Treats Underlying Cause of Cystic Fibrosis
5. Pharmacodynamic Data from Syndax Pharmaceuticals ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011
6. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
7. Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
8. Idenix to Host Conference Call Discussing Third Quarter and Nine Month 2011 Financial Results and Announces Presentations at the American Association for the Study of Liver Diseases Meeting (AASLD)
9. ADVENTRX and FDA Reach Agreement on Pivotal Study for ANX-514
10. FTC Study Finds that in FY 2011, Pharmaceutical Industry Continued to Make Numerous Business Deals that Delay Consumers Access to Lower-Cost Generic Drugs
11. Anthera Announces Last Patient Enrolled in PEARL-SC Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a locally ... business owners in North Central West Virginia, is embarking on a cooperative charity ... residents in the region. , The Stepping Stones organization offers a series of ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... from the American Heart Association (AHA) to launch a Rheumatic Heart Disease Center, ... prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... announced today that it has received certification for ANSI/ASIS PSC.1-2012. The company’s work ... in environments where the rule of law has been degraded. The PSC.1 standard ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
Breaking Medicine News(10 mins):